1. Home >
  2. M&A >
  3. Divestiture >
  4. Australia >
  5. XORTX Therapeutics Acquires Renal Anti-Fibrotic Therapeutic Program

M&A Deal Summary

XORTX Therapeutics Acquires Renal Anti-Fibrotic Therapeutic Program

On October 17, 2025, XORTX Therapeutics acquired life science company Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems for 3M AUD

Acquisition Highlights
  • This is XORTX Therapeutics’ 1st transaction in the Life Science sector.
  • This is XORTX Therapeutics’ 0th largest (disclosed) transaction.
  • This is XORTX Therapeutics’ 1st transaction in Australia.

M&A Deal Summary
Date 2025-10-17
Target Renal Anti-Fibrotic Therapeutic Program
Sector Life Science
Buyer(s) XORTX Therapeutics
Sellers(s) Vectus Biosystems
Deal Type Divestiture
Deal Value 3M AUD

Target

Renal Anti-Fibrotic Therapeutic Program

Rosebery, Australia
The Renal Anti-Fibrotic Therapeutic Program includes a novel new chemical entity, VB4-P5, along with its associated intellectual property, regulatory documentation, and manufacturing data. The program is currently at the pre-IND (Investigational New Drug) stage of development and targets both rare and prevalent forms of kidney disease — areas with substantial unmet medical need.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

XORTX Therapeutics

Calgary, Alberta, Canada
Category Company
Sector Life Science
DESCRIPTION

XORTX Therapeutics is a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease. XORTX Therapeutics is based in Calgary, Alberta.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
Country: Australia M&A 1 of 1
Year: 2025 M&A 1 of 1

Seller(S) 1

SELLER

Vectus Biosystems

Rosebery, Australia
Category Company
Sector Life Science
DESCRIPTION

Vectus Biosystems is a biotechnology company focused on the discovery and development of novel therapeutic compounds for fibrotic and cardiovascular diseases. Vectus Biosystems is headquartered in Rosebery, New South Wales.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
Country: Australia M&A 1 of 1
Year: 2025 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal